This page shows the publications co-authored by David Ryan and Dushyant Sahani.
Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with BRAF Mutation and 5-year Overall Survival. Radiol Imaging Cancer. 2020 09; 2(5):e190084.
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. N Engl J Med. 2010 Jun 24; 362(25):2411-9.
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54.
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. N Engl J Med. 2005 Jun 30; 352(26):2734-41.
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8.
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
Detection of liver metastases from gastrointestinal cancer: comparision of high resolution MnDPDP enhanced MRI and FDG-PET. Acad Radiol. 2005 May; 12 Suppl 1:S17-20.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.